Eric has a strong multidisciplinary background in metabolic disease and oncology targets with over 20 years of experience in the biotech/pharmaceutical industry. Prior to joining RayzeBio, he served as Vice President Development & Operations at Metacrine, Inc. a mid-stage clinical development company where he oversaw nonclinical development of the lead clinical assets for non-alcoholic steatohepatitis (NASH). Prior to Metacrine, he served as Senior Director of Operations at Seragon Pharmaceuticals and was involved in business development efforts resulting in the $1.7B acquisition of Seragon by Genentech, for an upfront payment of $725M and $1B in contingent development milestones. Prior to Ser agon, he served as Director of Operations at Aragon Pharmaceuticals on the development of apalutamide which was successfully commercialized following Aragon’s acquisition by Johnson & Johnson for $1B. In previous positions, Eric worked as a pharmacologist with numerous scientific publications on oncology and metabolic disease targets at companies including X-Ceptor Therapeutics, acquired by Exelixis, Ligand Pharmaceuticals and Hybritech, Inc. Eric is a graduate of the University of California at San Diego.

As president, Ben is responsible for the leadership of RayzeBio including the strategic growth of the company’s differentiated actinium-based radiopharmaceutical platform to enable rapid development of programs and therapies for the benefit of patients around the world. 

With over 20 years of industry experience, Ben joined RayzeBio in 2024 following the acquisition of Mirati Therapeutics where he was most recently chief commercial officer and head of business development. Prior to Mirati, Ben was senior vice president, chief commercial officer at Halozyme Therapeutics, where he was responsible for the global commercial strategy for the company’s oncology portfolio. Previously, Ben spent 17 years at Bristol Myers Squibb in various roles, including general manager, UK & Ireland, where he oversaw an organization of more than 300 people, and vice president Marketing, Immuno-Oncology. Ben received both his MBA and B.S. in management from St. John’s University in Queens, New York.